Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
30 July 2020 | Story Valentino Ndaba | Photo Anja Aucamp
Dr Fumane Khanare opted to integrate poetry into her teaching practice, using innovative ways to keep the curriculum afloat and interesting at the same time.
The Coronavirus (COVID-19) lockdown has severely affected teaching and learning. Lecturers and students alike have been challenged to explore innovative ways to keep the curriculum afloat and interesting at the same time. Dr Fumane Khanare, Senior Lecturer in the Faculty of Education, has opted to integrate poetry into her teaching practice. Her Community Psychology students have shifted over the past few months from merely interacting with the course material to generating their own content.

Learning in the times of lockdown

According to Dr Khanare, the psycho-social impact of COVID-19 remains unknown as the world grapples with a backlog of information, accompanied by loss and grief. However, collaborative strides are being made in the right direction, considering that this is unchartered territory. “Recommendations advocating for online teaching and learning, bidding for free data, and laptops for the majority of students, especially those at the peripheries of a mainstream economy – and of course physical distancing-adhering wellness programmes – may enable effective teaching and learning.” 

Why poetry?

“Lurched in at the deep end and taking into account the students who are not well-equipped with the integration of information and communications technology in learning, is significant. This realisation led me to seek ways to help my students develop a deeper understanding and critical-thinking skills, as well as becoming self-motivated students amid COVID-19,” explained Dr Khanare.

Students were first tasked with analysing the poetry of Butler-Kisber (2002). Thereafter, they were required to write poems about COVID-19, underpinned by the Community Psychology in Education module. “The activity provided students with an opportunity to use and reinforce concepts learnt prior to the lockdown, monitor their own understanding and progress, plus motivate them to come to the lecture prepared – a function known as co-creators of knowledge,” she said.

The artistic creations of these students were circulated among peers for review, allowing them to move from the peripheries to the centre of knowledge production amid a pandemic. 

Digitising the education space

Beyond the classroom, Dr Khanare will attend the 2020 Women Academics in Higher Education Virtual Symposium. As the co-convener of the World Education Research Association-International Research Network, she continues to ensure that research-related activities continue, despite a ban on international travel.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept